Stock comparison
Alvotech
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALVO
Alvotech
Market cap
$1.04B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALVO | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 70B | HAE |
| Benjamin Graham | 51D | 85A | HAE |
| Philip Fisher | 55C | 60C | HAE |
| Peter Lynch | 78C | 54C | ALVO |
| Joel Greenblatt | 45D | 31F | ALVO |
| Charlie Munger | 52D | 54D | HAE |
| Terry Smith | 43D | 55D | HAE |
Side-by-side metrics
| Metric | ALVO | HAE |
|---|---|---|
| Market cap | $1.04B | $2.98B |
| P/E (TTM) | 33.1x | 24.8x |
| EV/EBIT | 29.5x | 14.1x |
| ROIC (TTM) | 1.3% | 8.37% |
| Gross margin | 59.82% | 55.74% |
| Net margin | 4.76% | 7.29% |
| Revenue CAGR 5y | 99.83% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | - | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALVO leads on
- Debt / Equity-vs 1.5x+130%
- Revenue CAGR 5y99.83%vs 7.65%+92%
- Gross margin59.82%vs 55.74%+7%
HAE leads on
- ROIC (TTM)8.37%vs 1.3%+84%
- Market cap$2.98Bvs $1.04B+65%
- EV/EBIT14.1xvs 29.5x+52%
- Net margin7.29%vs 4.76%+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.